TREMFYA® (guselkumab) is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.3 TREMFYA® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.3
Information about this product, including side effects, precautions, contraindications and dosing and administration can be found at https://www.janssen-pi.co.uk/tremfya. Prescribers are recommended to consult the summary of product characteristics before prescribing.
Abbreviations: NICE, National Institute for Health and Care Excellence; JAK, Janus Kinase Inhibitor
References: 1.© National Institute for Health and Care Excellence [2025]. Guselkumab for previously treated moderately to severely active Crohn's disease [TA11245]. Available from https://www.nice.org.uk/guidance/ta1095/chapter/1-Recommendations.
All rights reserved. Subject to Notice of rights 2. © National Institute for Health and Care Excellence [2025]. Guselkumab for treating moderately to severely active ulcerative colitis [TA11247]. Available from https://www.nice.org.uk/guidance/ta1094/chapter/1-Recommendations. 3. TREMFYA® (guselkumab) Summary of Product Characteristics.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
